87 related articles for article (PubMed ID: 1058832)
21. Proceedings: The thymic hormone and cellular immunity.
Odling-Smee GW; Camblin JG; Roy AD
Br J Surg; 1975 Feb; 62(2):162. PubMed ID: 1054283
[No Abstract] [Full Text] [Related]
22. [In vitro antitumor immune response induced by fusion of dendritic cells and Ewing's sarcoma cells].
Tang S; Guo W; Guo Y; Qu HY; Li DS
Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(12):803-6. PubMed ID: 16083585
[TBL] [Abstract][Full Text] [Related]
23. Tumor-specific cellular cytotoxicity to human sarcomas: evidence for a cell-mediated host immune response to a common sarcoma cell-surface antigen.
Cohen AM; Ketcham AS; Morton DL
J Natl Cancer Inst; 1973 Mar; 50(3):585-9. PubMed ID: 4513520
[No Abstract] [Full Text] [Related]
24. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas.
Ulaner GA; Hoffman AR; Otero J; Huang HY; Zhao Z; Mazumdar M; Gorlick R; Meyers P; Healey JH; Ladanyi M
Genes Chromosomes Cancer; 2004 Oct; 41(2):155-62. PubMed ID: 15287028
[TBL] [Abstract][Full Text] [Related]
25. Blocking of oncofoetal cross-reactivity in human osteogenic sarcoma with solubilized tumour antigen.
Agashe SS; Gangal SG; Nair PN; Rao RS
Indian J Med Res; 1977 Nov; 66(5):824-31. PubMed ID: 273007
[No Abstract] [Full Text] [Related]
26. Cellular immunity to human sarcoma.
Vánky F; Stjernswärd J; Nilsonne U
J Natl Cancer Inst; 1971 Jun; 46(6):1145-51. PubMed ID: 4932427
[No Abstract] [Full Text] [Related]
27. Concentration of soluble CD44 standard and soluble CD44 variant V5 in the serum of patients with malignant bone tumors.
Holzer G; Kittl E; Pfandelsteiner T; Trieb K; Kotz R
Med Pediatr Oncol; 2003 Jan; 40(1):64-5. PubMed ID: 12426692
[No Abstract] [Full Text] [Related]
28. [Clinical picture of osteogenic sarcoma, osteogenic chondrosarcoma and Ewing's sarcoma].
Stefański W; Guzecki A
Pol Przegl Chir; 1971 Feb; 43(2):149-54. PubMed ID: 5279594
[No Abstract] [Full Text] [Related]
29. Cytotoxicity of lymphocytes to established cultures of human tumors: evidences for specificity.
Sinkovics JG; Tebbi K; Cabiness JR
Natl Cancer Inst Monogr; 1973 Jun; 37():9-18. PubMed ID: 4123456
[No Abstract] [Full Text] [Related]
30. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.
Zhou Z; Lafleur EA; Koshkina NV; Worth LL; Lester MS; Kleinerman ES
Mol Cancer Res; 2005 Dec; 3(12):685-91. PubMed ID: 16380506
[TBL] [Abstract][Full Text] [Related]
31. A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies.
Donner L; Triche TJ; Israel MA; Seeger RC; Reynolds CP
Prog Clin Biol Res; 1985; 175():347-66. PubMed ID: 3991736
[No Abstract] [Full Text] [Related]
32. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
[TBL] [Abstract][Full Text] [Related]
33. Autoradiographic in vitro study of the cell kinetics of osteogenic sarcomas and Ewing's sarcomas in children.
Willnow U
Arch Geschwulstforsch; 1982; 52(1):9-16. PubMed ID: 6952823
[TBL] [Abstract][Full Text] [Related]
34. Possible differential diagnosis of neuroblastoma from rhabdomyosarcoma and Ewing's sarcoma by using a panel of monoclonal antibodies.
Sugimoto T; Sawada T; Arakawa S; Matsumura T; Sakamoto I; Takeuchi Y; Reynolds CP; Kemshead JT; Helson L
Jpn J Cancer Res; 1985 Apr; 76(4):301-7. PubMed ID: 3924704
[TBL] [Abstract][Full Text] [Related]
35. Procollagens as markers for the cell of origin of human bone tumors.
Stern R; Wilczek J; Thorpe WP; Rosenberg SA; Cannon G
Cancer Res; 1980 Feb; 40(2):325-8. PubMed ID: 6927962
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy.
Sears HF; Simon R; Rosenberg SA
Cancer Treat Rep; 1980; 64(4-5):589-97. PubMed ID: 6933004
[TBL] [Abstract][Full Text] [Related]
38. Ewing's sarcoma of the maxilla.
Zheng P; Lu X; Zheng K
Chin Med J (Engl); 1998 Apr; 111(4):377-8. PubMed ID: 10374409
[No Abstract] [Full Text] [Related]
39. [Immunohistochemical studies of Ewing's sarcomas and their differential diagnosis with other "small round blue cell" sarcomas of childhood and adolescence].
Llombart-Bosch A; Perez-Bacete M; Triche TJ
Verh Dtsch Ges Pathol; 1986; 70():321-4. PubMed ID: 3548136
[No Abstract] [Full Text] [Related]
40. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
